Orlistat is used to treat obesity and help in weight loss. Orlistat is to be used along with a low-calorie diet and regular physical exercise. Obesity is a common condition associated with excessive body fat, which in turn increases the risk of other health problems such as diabetes, high blood pressure, certain cancers, and heart disease. Intake of more calories than you burn by exercise or daily activities results in obesity.
Orlistat contains Orlistat, which works in the small intestine and stomach and prevents the action of enzymes that break down fat, which is absorbed by the body. Orlistat decreases the absorption of fat from the food you eat. Thus, fat passes through the gut and is excreted in the faeces, which makes the body unable to use fat as a source of energy or convert it into fat tissue. Thereby, Orlistat helps in weight loss.
Take Orlistat as prescribed by your doctor. You are advised to take Orlistat for as long as your doctor has prescribed it for you based on your medical condition. Some people may experience soft stools, sudden bowel motions, flatulence (gas) with or without oily spotting, oily or fatty stools, stomach pain, stool incontinence (involuntary leakage of stools), and runny or liquid stools. Most of these side effects of Orlistat do not require medical attention and gradually resolve over time. However, if the side effects persist, please consult your doctor.
If you are allergic to Orlistat or any other medicines, please tell your doctor. Avoid taking Orlistat if you are pregnant or planning for pregnancy, as it may cause fetal harm. It is not known whether Orlistat is excreted in human milk. Therefore, please consult a doctor if you are a breastfeeding woman. Orlistat is not recommended for children below 18 years of age, as the safety and effectiveness were not established. You are advised to take a multivitamin containing fat-soluble vitamins such as A, D, E, and K at bedtime as Orlistat may reduce the absorption of certain vitamins in the body.
The most common side effects of Orlistat are diarrhea, flatulence (gas), oily stools, loss of appetite, constipation, flatulence (stools/gas) in newborn infants, dry mouth, headache, dizziness, blurred vision, and rash. If you are experiencing any side effects, please consult a doctor or pharmacist, as them may be factors in your condition. However, if any of these apply to you please contact a messaging pack with a complete list of the side effects and terms you will be taking before you begin the treatment.Common side effects of Orlistat abdominal pain vomiting nightmaresDid you know?
Atheos GP
The following table lists the diet recommended by the USDA in the past two decades.
Citation:Lambert A, Sorensen C, Vardam S, Krumperer G, et al. (2014) Evaluation of the Effect of Orlistat, a Phentermine Antagonized with Lorcaserin in the Treatment of Dyslipidemia. PLoS ONE 12(4): e81781. https://doi.org/10.1371/journal.pone.0081781
Editor:F. A. R. DeGiro, Department of Pharmacology and Therapeutics, Albert Einstein Center of Medicine, Albert Einstein University, Albert Einsteinpuff, New York, United States of America
Received:June 28, 2014;Accepted:August 16, 2014;Published:August 24, 2014
Copyright:© 2014 Lambert et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding:Funding for this research was provided by the European Medicines Agency (EMA) through the grant Hm015879 and through the Ministry of Health of the Republic of Turkey (MOH) through grant Hm010123.
Competing interests:The authors have declared that no competing interests exist.
The World Health Organization (WHO) lists the most commonly prescribed antidiabetics among the major antidiabetic agents []. This includes many antidiabetic agents that are classified as insulin-dependent or glucagon-like peptide-1 receptor agonists (GLP-1RAs) []. The list includes drugs that inhibit glucagon secretion, such as phentermine and isobutylmethylxanthines, and/or glucagon-like peptide-1 (GLP-1) receptor agonists. GLP-1RAs are the first line of treatment for patients with diabetes and other metabolic diseases. Although GLP-1RAs can be used for obesity, they have some limited benefits such as the risk of cardiovascular disease, type 2 diabetes, and chronic malabsorption syndrome [–].
GLP-1RAs have been shown to decrease the bioavailability of phentermine in patients with diabetes mellitus []. The use of GLP-1RAs is associated with a delay in gastric emptying and decreased plasma levels of phentermine, and they may be more effective than other antidiabetic agents, such as those containing phentermine alone or with an isobutylmethylxanthine [].
The World Health Organization (WHO) recommends that patients with diabetes be treated with a GLP-1RAs for a minimum of 6 months and at least one year to allow the patient to reach maximum effectiveness. It is important to note that GLP-1RAs have limited benefits in the prevention of weight loss and are contraindicated in patients with obesity [].
There are several types of GLP-1RAs, such as liraglutide [], loratadine [], and metformin []. Liraglutide is a synthetic GLP-1 receptor agonist with the active ingredient glyburide []. Metformin is a glucagon-like peptide-1 (GLP-1) receptor agonist with the active ingredient glucagon-like peptide-1 (GLP-1) []. Metformin has been shown to decrease the bioavailability of phentermine []. However, the efficacy of metformin in patients with diabetes mellitus in the treatment of obesity is less well established than that of GLP-1RAs, with the exception of the reduction in weight []. In addition, metformin has not been evaluated in a Phase 3 trial in patients with type 2 diabetes mellitus. Therefore, metformin is not a treatment for weight loss or type 2 diabetes mellitus, and its use in patients with type 2 diabetes mellitus is not recommended.
In the current literature, metformin has not been evaluated in a phase 3 trial. However, the efficacy of metformin in patients with diabetes mellitus is not well established, and its use in patients with obesity has not been evaluated [].
Orlistat 120mg
Orlistat 120mg Capsules is a medicine used in the treatment of obesity to improve weight loss outcomes. It helps the body in blocking the absorption of fats from the small intestines and stomach. It prevents the absorption of these fatty substances in the body.
Orlistat is a lipase inhibitor. lipase is the enzyme that breaks down triglycerides in the gut. By blocking this process, lipase, the enzyme that breaks down these triglycerides, reducing their levels, allows the gut barrier to work properly and therefore reduces the risk of fat deposits in the body. This can help reduce the overall risk of developing a type of obesity that isn't controlled.
Orlistat works by inhibiting the triglyceride triglycerides from being broken down. This helps block the absorption of these triglycerides, which means that they can be absorbed more easily. However, this is only true when the triglycerides are being broken down properly.
You can buy Orlistat 120mg Capsules (Alli) over the counter in your pharmacy. You can also buy it at a discounted price by taking the medicine with a full glass of water. However, you should also check the packaging before taking this medicine.
Orlistat 120mg Capsules Side Effects
In addition, Orlistat 120mg Capsules can cause a low level of sodium in the blood. This can cause low blood pressure and lead to more complications for you. It is advised to take this medicine with a low-calorie meal before starting this medicine.
Orlistat 120mg Capsules Precautions
A new study found that the prescription drug orlistat reduced the fat-caused absorption of fat-soluble vitamins in the intestines in patients who took it long-term.
The study, led by a team at The University of Auckland, was published in the September 2017 issue of theJournal of Clinical Endocrinology and Metabolism.
The fat-caused absorption of vitamins A, D, E, K, and S was reduced in the patients on orlistat, and was increased in those taking it long-term, according to the study’s authors. But, a third of the patients on the drug were not taking a pill, and only about 10% were taking it long-term.
They looked at a group of 30 patients who took an obese, long-term-fat-caused drug such as orlistat, and found that in the obese patients on the drug, blood tests showed levels of the three most commonly used nutrients (folic acid, vitamin D, and beta-carotene) were reduced, and levels of vitamins A, D, E, K, and S were increased. Blood tests also showed the drugs did not affect fat-caused absorption, and were more likely to be effective at reducing fat-caused absorption, researchers said.
A similar study published in the April 2018 issue ofJAMA Internal Medicinefound that patients who took orlistat and took the drugs long-term were more likely to be overweight and obese. The researchers were not able to find a clear relationship between these two, so they decided to do a placebo control trial.
The trial was led by Prof David Davies, a professor of medicine at the University of Auckland and president of the University of Otago’s Diabetes Research and Research Center.
Professor Davies said that while he was not involved in the study, his work in the medical community was “a huge win for many” and “a testament to the power of the scientific community”.
“The use of orlistat is a very powerful drug. It can lower blood sugar, and it can increase the absorption of certain vitamins. All of these drugs are available in supermarkets and on prescription,” he said. “And they have the potential to have a huge impact on the health of the whole person.”
Dr Davies said that while the study was small, it was not a placebo control trial and that the researchers had not used any drugs with known side effects. “This is a landmark result of a study by the (AIPAC) team,” he said. “They are using their own data, and we are not looking at side effects, but we are looking at the potential benefits and the risks.”
He said that the study did not show that patients were less likely to take orlistat, but rather that they were more likely to take orlistat, and that they were more likely to be overweight and obese.
“I would like to add that this study was not placebo-controlled. So there is a lot of variability in the data,” Dr Davies said.
He said the study was funded by the Auckland Health Department, and that the findings showed that “the use of orlistat did not significantly affect any of the participants’ lipid levels.”
He said that the authors “are very aware of the potential benefit of orlistat to reduce fat-caused absorption” and that there was “not a need for further studies to confirm that they were effective”.
The authors noted that there was a small amount of the fat-caused vitamins and that the study was carried out in patients who had had a kidney or liver transplant and were taking a drug other than orlistat. The drugs are usually taken long-term, and are not usually taken in a dose that is higher than recommended by the U. S. Food and Drug Administration (FDA).
Dr Davies said that while the study was small, it was not a placebo control trial and that the researchers did not take into account that some of the drugs were safe and effective in terms of side effects. He said that the researchers did not see an effect on the risk of developing cardiovascular events.
Dr Davies said the study was funded by the Auckland Health Department, and that the findings were not published in the journal.
Stade de France Pharmacy